Insider Buying: OncoCyte Co. (NASDAQ:OCX) Major Shareholder Purchases $7,066,400.00 in Stock

OncoCyte Co. (NASDAQ:OCX) major shareholder Broadwood Partners, L.P. bought 2,420,000 shares of the business’s stock in a transaction on Thursday, April 11th. The stock was bought at an average price of $2.92 per share, with a total value of $7,066,400.00. Following the purchase, the insider now owns 4,929,066 shares in the company, valued at $14,392,872.72. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

OncoCyte Stock Down 5.8 %

Shares of OCX opened at $2.59 on Thursday. OncoCyte Co. has a 1-year low of $2.08 and a 1-year high of $6.80. The firm’s 50 day simple moving average is $2.95 and its 200 day simple moving average is $3.06.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. StockNews.com assumed coverage on shares of OncoCyte in a research report on Thursday. They issued a “sell” rating for the company. Stephens reissued an “equal weight” rating and issued a $4.00 price target on shares of OncoCyte in a report on Wednesday. Finally, Benchmark reaffirmed a “speculative buy” rating and issued a $5.00 price target on shares of OncoCyte in a report on Monday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $3.90.

Institutional Trading of OncoCyte

A number of hedge funds have recently made changes to their positions in OCX. Vanguard Group Inc. increased its stake in OncoCyte by 3.2% in the fourth quarter. Vanguard Group Inc. now owns 247,873 shares of the company’s stock valued at $620,000 after acquiring an additional 7,784 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of OncoCyte by 131.7% during the 2nd quarter. Renaissance Technologies LLC now owns 138,100 shares of the company’s stock valued at $32,000 after purchasing an additional 78,500 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of OncoCyte by 23.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,228,553 shares of the company’s stock valued at $283,000 after buying an additional 236,099 shares in the last quarter. Balyasny Asset Management LLC raised its holdings in shares of OncoCyte by 389.9% during the 3rd quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after buying an additional 42,091 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in OncoCyte by 17.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 541,983 shares of the company’s stock worth $487,000 after buying an additional 81,979 shares during the last quarter. 55.35% of the stock is owned by institutional investors.

About OncoCyte

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.